| Industry-sponsored ( N  = 136) | Non-sponsored ( N  = 208) | Publicly-sponsored ( N  = 314) | Overall ( N  = 658) |
---|---|---|---|---|
Continent of corresponding author | ||||
 Africa | 1 (1%) | 3 (1%) | 0 (0%) | 4 (1%) |
 Asia | 11 (8%) | 92 (45%) | 161 (50%) | 264 (40%) |
 Australia | 1 (1%) | 3 (1%) | 2 (1%) | 6 (1%) |
 Europe | 71 (52%) | 56 (27%) | 80 (26%) | 207 (31%) |
 North America | 52 (38%) | 44 (21%) | 63 (20%) | 159 (24%) |
 Oceania | 0 (0%) | 3 (1%) | 2 (1%) | 5 (1%) |
 South America | 0 (0%) | 7 (4%) | 6 (2%) | 13 (2%) |
Disease category | ||||
 Allergy and immunology | 2 (2%) | 0 (0%) | 0 (0%) | 2 (0%) |
 Cardiology | 9 (7%) | 27 (13%) | 20 (5%) | 56 (9%) |
 Dermatology | 6 (4%) | 8 (4%) | 9 (3%) | 23 (3%) |
 Endocrinology | 19 (14%) | 15 (7%) | 37 (11%) | 71 (11%) |
 Gastroenterology | 6 (4%) | 23 (11%) | 27 (8%) | 56 (9%) |
 Hematology | 7 (5%) | 6 (3%) | 8 (3%) | 21 (3%) |
 infectious disease | 9 (7%) | 17 (8%) | 24 (8%) | 50 (8%) |
 Neurology | 12 (9%) | 14 (7%) | 16 (5%) | 42 (6%) |
 Obstetrics and gynecology | 1 (1%) | 4 (2%) | 6 (2%) | 11 (2%) |
 Oncology | 17 (12%) | 32 (15%) | 50 (16%) | 99 (15%) |
 Ophthalmology | 1 (1%) | 1 (1%) | 6 (2%) | 8 (1%) |
 Psychiatry | 7 (5%) | 14 (7%) | 24 (8%) | 45 (7%) |
 Respirology | 15 (11%) | 10 (5%) | 15 (5%) | 40 (6%) |
 Rheumatology | 21 (15%) | 13 (6%) | 40 (13%) | 74 (11%) |
 Urology | 4 (3%) | 2 (1%) | 7 (2%) | 13 (2%) |
 Dentistry | 0 (0%) | 4 (2%) | 2 (1%) | 6 (1%) |
 General Surgery | 0 (0%) | 3 (1%) | 4 (1%) | 7 (1%) |
 Nephrology | 0 (0%) | 10 (5%) | 14 (5%) | 24 (3%) |
 Orthopedic surgery | 0 (0%) | 3 (1%) | 3 (1%) | 6 (1%) |
 Pediatrics | 0 (0%) | 2 (1%) | 2 (1%) | 4 (1%) |
Outcome typea | ||||
 Objective | 48 (35%) | 41 (20%) | 77 (25%) | 166 (25%) |
 Semi-objective | 25 (19%) | 48 (23%) | 72 (23%) | 145 (22%) |
 Subjective | 63 (46%) | 119 (57%) | 165 (52%) | 347 (53%) |
Efficacy or safety outcomea | ||||
 Efficacy | 131 (96%) | 179 (86%) | 288 (92%) | 598 (91%) |
 Safety | 5 (4%) | 29 (14%) | 26 (8%) | 60 (9%) |
Type of treatment comparison | ||||
 Pharmacologic vs pharmacologic | 37 (27%) | 71 (34%) | 93 (30%) | 201 (30%) |
 Pharmacologic vs placebo | 99 (73%) | 137 (66%) | 221 (70%) | 457 (70%) |
Number of RCTs in NMAa | ||||
 Median [IQR] | 20 [12–33] | 17 [11–33] | 22 [13–44] | 20 [12–37] |
 Not reported | 4 (3%) | 3 (1%) | 0 (0%) | 7 (1%) |
Number of participants in NMAa | ||||
 Median [IQR] | 7765 [4332–17150] | 4992 [2987–13806] | 6515 [2722–18247] | 6283 [3071–16230] |
 Not reported | 32 (24%) | 24 (11%) | 16 (5%) | 72 (11%) |
Number of interventions in NMAa | ||||
 Median [IQR] | 8 [6–11] | 7 [5–9] | 7 [5–10] | 7 [5–10] |
 Not reported | 4 (3%) | 2 (1%) | 0 (0%) | 6 (1%) |
Number of nodes in NMAa | ||||
 Median [IQR] | 8 [6–11] | 7 [5–10] | 8 [6–12] | 8 [5–11] |
 Not reported | 6 (4%) | 3 (1%) | 0 (0%) | 9 (1%) |
Number of interventions manufactured by the industry sponsor in NMAa | ||||
 Median [IQR] | 1 [1, 2] | NA [NA–NA] | NA [NA–NA] | 1 [1, 2] |
 Not reported | 0 (0%) | 208 (100%) | 314 (100%) | 522 (79%) |